Mobilise-D-Facebook cover - 02

Connecting digital mobility assessment to clinical outcomes
for regulatory and clinical endorsement



Mobilise-D is a 5-year, IMI-funded project that will produce validated and accepted digital mobility outcomes to monitor daily life gait of people with different mobility problems, with the goal to improve follow-up and personalized care.



Mobilise-D will perform a technical and clinical validation of a sensor-algorithm pair in different patient groups. We maintain close dialogue with the European Medicines Agency (EMA) to facilitate the process of regulatory approval.



The Mobilise-D consortium consists of 34 partners from Europe and the USA. Over 150 professionals with technical, clinical, and regulatory expertise will work together to bring digital mobility outcomes to the clinic.                                                                  

Mobility – how well we walk – is an important marker of health; a slow walking speed is associated with greater mortality, morbidity, cognitive decline, dementia, and fall risk. As the population ages, the number of people experiencing mobility challenges is expected to rise. However, accurately assessing people’s mobility, especially in the real daily life world, is far from easy.

Mobilise-D will develop a comprehensive system to monitor and evaluate people’s gait based on digital technologies, including sensors worn on the body. The project focuses on conditions which often affect mobility, namely chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure.

The Mobilise-D results will help to improve the accurate assessment of daily life mobility in clinical trials and patient treatment, thereby contributing to improved and more personalised care.

Patient Groups

Mobilise-D will focus on five different patient groups that together represent respiratory problems (chronic obstructive pulmonary disease – COPD), neurodegenerative conditions (Parkinson’s disease – PD), neuroinflammatory problems (multiple sclerosis – MS), osteoporosis and sarcopenia (hip fracture recovery/proximal femoral fracture – PFF), and cardiac pathology (congestive heart failure – CHF).

These patient groups cover a range of walking speed, mobility challenges, and potential events that we care about, such as improving versus worsening of function, falls, hospitalisation, nursing home admission, and death. Furthermore, these patient groups will be followed at 12 different sites across Europe, ensuring a good geographical representation and covering a diverse representation of health care organisation, such as in- versus outpatient care, as well as public versus private health services.

Read More

Twitter Feed

Our colleagues from Tel Aviv, the TASMC Mobilisers, studied the quality of walking of people with multiple sclerosis and healthy controls in laboratory and real-life environments. Read the full paper here:
#MobiliseD #wearables #MultipleSclerosis
Mobilise_D photo

We stand by our Italian colleagues and all Italy during these trying times! We send our support and solidarity to all countries in Europe and worldwide affected by #COVID19! Stay safe and healthy everyone! @EU_Commission @EU_Health @IMI_JU
Mobilise_D photo
European Commission 🇪🇺 @EU_Commission
We stand by Italy during these trying times. 🇮🇹🇪🇺

Share your words of support for our Italian friends here – we will pass them on to our Italian audience!

They are our colleagues, friends and EU family.

❤️ Cari amici, siamo con voi. #COVID19

Latest News

Walking in the lab and a real-world environment with Multiple Sclerosis

Our colleagues from Tel Aviv, the TASMC Mobilisers, studied the quality of walking of people with multiple sclerosis and healthy controls in two environments: a) a well-structured laboratory setting and b) during real-life, everyday walking using 24/7 monitoring.  During every-day walking, the patients took fewer steps, they walked more slowly, and the quality of their…

Upcoming Events